Literature DB >> 7533167

Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase.

C Palaniappan1, P J Fay, R A Bambara.   

Abstract

The action of the dipyridodiazepinone nevirapine (BI-RG-587) on polymerization and RNase H activities of human immunodeficiency virus reverse transcriptase (RT) was examined. Substrates using heteropolymeric DNA primers hybridized to complementary RNA templates were employed. Challenged assays were performed that allowed measurement of activity of the RT resulting from a single round of binding of RT to substrate. Results demonstrated that nevirapine alters the cleavage specificity of the RNase H. Instead of a primary cleavage approximately 18 nucleotides upstream of the DNA 3' terminus, multiple cleavages were observed ahead of and behind this site. This indicated that the compound facilitates sliding of the RT away from the DNA primer terminus allowing cleavage at more sites. The change in specificity occurred whether the primer terminus was at the end or internal on the template. Experiments with RNA primers on circular DNA demonstrated a nevirapine-induced stimulation of RNase H activity beyond the increase expected from the change in cleavage specificity. Examination of polymerization showed that the compound decreased both the number of primers that underwent synthesis and the processive elongation of those primers. The significance of these results with respect to viral replication and recombination is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533167     DOI: 10.1074/jbc.270.9.4861

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

2.  Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.

Authors:  Jiong Wang; Gang Zhang; Robert A Bambara; Dongge Li; Hua Liang; Hulin Wu; Hannah M Smith; Nicholas R Lowe; Lisa M Demeter; Carrie Dykes
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  Efavirenz stimulates HIV-1 reverse transcriptase RNase H activity by a mechanism involving increased substrate binding and secondary cleavage activity.

Authors:  John M Muchiri; Dongge Li; Carrie Dykes; Robert A Bambara
Journal:  Biochemistry       Date:  2013-07-09       Impact factor: 3.162

4.  Molecular dynamics study of HIV-1 RT-DNA-nevirapine complexes explains NNRTI inhibition and resistance by connection mutations.

Authors:  R S K Vijayan; Eddy Arnold; Kalyan Das
Journal:  Proteins       Date:  2013-11-22

5.  Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases.

Authors:  Francesca Esposito; Tatyana Kharlamova; Simona Distinto; Luca Zinzula; Yung-Chi Cheng; Ginger Dutschman; Giovanni Floris; Patrick Markt; Angela Corona; Enzo Tramontano
Journal:  FEBS J       Date:  2011-03-16       Impact factor: 5.542

6.  A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

7.  Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.

Authors:  Dirk Jochmans; Jérôme Deval; Bart Kesteleyn; Herwig Van Marck; Eva Bettens; Inky De Baere; Pascale Dehertogh; Tania Ivens; Marcia Van Ginderen; Bertrand Van Schoubroeck; Maryam Ehteshami; Piet Wigerinck; Matthias Götte; Kurt Hertogs
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

8.  Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain.

Authors:  Martin T Christen; Lakshmi Menon; Nataliya S Myshakina; Jinwoo Ahn; Michael A Parniak; Rieko Ishima
Journal:  Chem Biol Drug Des       Date:  2012-08-31       Impact factor: 2.817

9.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

10.  HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition.

Authors:  Greg L Beilhartz; Michaela Wendeler; Noel Baichoo; Jason Rausch; Stuart Le Grice; Matthias Götte
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.